<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04506658</url>
  </required_header>
  <id_info>
    <org_study_id>07-20 from 15.04.2020</org_study_id>
    <nct_id>NCT04506658</nct_id>
  </id_info>
  <brief_title>Efficiency and Safety of High-frequency Radio Wave Electrotherapy With a Radio Frequency of 448 kHz in the Treatment of Patients With Organic Erectile Dysfunction.</brief_title>
  <official_title>Efficiency and Safety of High-frequency Radio Wave Electrotherapy With a Radio Frequency of 448 kHz in the Treatment of Patients With Organic Erectile Dysfunction.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>I.M. Sechenov First Moscow State Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>I.M. Sechenov First Moscow State Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficiency and safety of high-frequency radio wave electrotherapy with a radio frequency of&#xD;
      448 kHz in the treatment of patients with organic erectile dysfunction. Sham comparator,&#xD;
      parallel study including both the main and control group to demonstrate the efficiency of the&#xD;
      device to treat erectile dysfunction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives of this study are:&#xD;
&#xD;
        -  To evaluate the effectiveness of the course treatment with the apparatus for continuous&#xD;
           capacitive resistive monopolar electrotherapy with a radio frequency of 448 kHz in&#xD;
           patients with organic erectile dysfunction.&#xD;
&#xD;
        -  Assess the safety and tolerability of continuous capacitive resistive monopolar&#xD;
           electrotherapy with a radio frequency of 448 kHz in patients with organic erectile&#xD;
           dysfunction.&#xD;
&#xD;
        -  To evaluate the duration of the effect of continuous capacitive resistive monopolar&#xD;
           electrotherapy with a radio frequency of 448 kHz.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A statistically significant increase in the number of points IIEF-5</measure>
    <time_frame>Through study completion, an average of 3 months after first procedure</time_frame>
    <description>IIEF-5</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>A statistically significant increase in penile blood flow.</measure>
    <time_frame>Through study completion, an average of 3 months after first procedure</time_frame>
    <description>According to Doppler</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statistically significant increase in SEP scores (Sexual Encounter Profile)</measure>
    <time_frame>Through study completion, an average of 3 months after first procedure</time_frame>
    <description>Schramek grading system score for assessing penile rigidity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>high-frequency radio wave electrotherapy with a frequency of 448 kHz on the penis structures.</intervention_name>
    <description>Patient in lithotomy position (supine) with return plate at lumbar level.&#xD;
Start with high power (within the allowed range) to get a faster hyperthermia and slowly decrease this percentage as the current builds up in the patient's body.&#xD;
Patients are undergoing high-frequency radio wave electrotherapy 2 times a week (12 procedures at all).</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>high-frequency radio wave electrotherapy with a frequency of 448 kHz on the penis structures.</intervention_name>
    <description>Doctor uses sham sensor to reduce efficiency to zero.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients aged 18 to 79 years;&#xD;
&#xD;
          2. The diagnosis is confirmed by assessing the functional criteria of arterial factors of&#xD;
             panel hemodynamics (dopplerography);&#xD;
&#xD;
          3. The diagnosis is confirmed by the assessment of the IIEF-5 questionnaire&#xD;
&#xD;
          4. Patients with organic erectile dysfunction lasting at least 6 months.&#xD;
&#xD;
          5. Patients with IIEF from 6 to 22 points.&#xD;
&#xD;
          6. Patients with a permanent sexual partner for more than 3 months;&#xD;
&#xD;
          7. Sexually Active Patients.&#xD;
&#xD;
        Non-inclusion criteria:&#xD;
&#xD;
          1. The use of other treatments for erectile dysfunction&#xD;
&#xD;
          2. Age under 18 and over 79 years old;&#xD;
&#xD;
          3. Anatomical deformation of the penis (angulation, cavernous fibrosis or Peyronie's&#xD;
             disease);&#xD;
&#xD;
          4. The presence of diseases predisposing to the development of priapism (sickle cell&#xD;
             anemia, multiple myeloma, leukemia, thrombocytopenia);&#xD;
&#xD;
          5. Running coagulation disorders;&#xD;
&#xD;
          6. The presence of tumors in the area of electrotherapy;&#xD;
&#xD;
          7. The presence of aneurysms in the propagation of radio frequency waves;&#xD;
&#xD;
          8. Angina pectoris;&#xD;
&#xD;
          9. Myocardial infarction, stroke, life-threatening arrhythmias;&#xD;
&#xD;
         10. Thrombosis, thromboembolic disease;&#xD;
&#xD;
         11. Arterial hypertension (blood pressure ≥ 170/90 mm Hg) or hypotension (blood pressure ≤&#xD;
             90/50 mm Hg.);&#xD;
&#xD;
         12. The patient has a mental illness that does not allow an assessment of the&#xD;
             effectiveness of therapy; history of alcoholism and drug addiction;&#xD;
&#xD;
        14. Active tuberculosis, chronic somatic diseases in the acute stage; 15. Condition after&#xD;
        coronary artery bypass grafting (CABG); 16. Patient's involvement in another clinical trial&#xD;
        in the last 3 months;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Serious unwanted phenomenons associated with exposure to the apparatus.&#xD;
&#xD;
          2. Incorrect inclusion in the study.&#xD;
&#xD;
          3. A marked deterioration in the patient's condition due to an increase in the severity&#xD;
             of the disease or the attachment of another disease.&#xD;
&#xD;
          4. The patient's appearance of non-inclusion criteria during the study.&#xD;
&#xD;
          5. Serious deviation from the protocol.&#xD;
&#xD;
          6. The desire of the patient or his legal representative.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dmitry Korolev, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sechenov University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dmitry Enikeev, M.D., Ph.D.</last_name>
    <phone>89267677873</phone>
    <email>dvenikeev@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dmitry Korolev, M.D.</last_name>
    <phone>89267677873</phone>
    <email>korolevdmitryo@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institute for Urology and Reproductive Health, Sechenov University.</name>
      <address>
        <city>Moscow</city>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dmitry Enikeev, M.D., Ph.D</last_name>
      <phone>+79267677873</phone>
      <email>enikeev-dv@1msmu.ru</email>
    </contact>
    <contact_backup>
      <last_name>Dmitry Korolev, MD</last_name>
      <phone>+79267677873</phone>
      <email>marktaratkin@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>http://www.sechenov.ru</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.urologypro.ru</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 6, 2020</study_first_submitted>
  <study_first_submitted_qc>August 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2020</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>I.M. Sechenov First Moscow State Medical University</investigator_affiliation>
    <investigator_full_name>Dmitry Enikeev, MD, PhD</investigator_full_name>
    <investigator_title>Director for Research</investigator_title>
  </responsible_party>
  <keyword>high-frequency radio wave electrotherapy</keyword>
  <keyword>radio frequency</keyword>
  <keyword>448 kHz</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

